PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 2026RSC Medicinal Chemistry0 citations

Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia

PLPing LiHRHaiyan RenXLXinyan Lan

Key Points

  • Identify and evaluate GBA-16-24 as a selective ATR inhibitor for treating FLT3-mutated acute myeloid leukemia.
  • Screening of ATR inhibitors
  • Assessment of GBA-16-24 potency
  • Evaluation of selective targeting in cancer cells
  • GBA-16-24 demonstrated high potency in inhibiting ATR
  • Effectively reduced cancer cell proliferation in FLT3-mutated AML
  • Showed minimal impact on normal cells, indicating selectivity

Abstract

Ataxia telangiectasia mutations and RAD3-related (ATR) kinase supports cancer cell survival via managing DNA damage or replication stress in various cancers, including acute myeloid leukemia (AML). Pharmacological inhibition of ATR...

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69a91dc3d6127c7a504c0f39https://doi.org/10.1039/d5md01005e
Ask AI
Helpful
Bookmark
Share
View Full Paper